Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of California, San Francisco
This study will investigate the effectiveness of MBCT as a primary treatment for MDD. Twelve unmedicated subjects with MDD were enrolled in the study. All subjects with MDD underwent depression severity assessment at baseline and after the 8-week intervention was complete to measure change. In addition, the subjects underwent blood sampling at the same time points to measure C-Reactive Protein change over the 8 weeks.
The primary goal of this pilot study is to determine the efficacy of MBCT as a primary treatment for adults with MDD. We will also measure change in the inflammatory biomarker C-Reactive Protein for an examination of the effects of depression treatment on this measure.
Age
18–60
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
English speaking
Able to give informed consent
DSM-IV (SCID) Diagnosis of Major Depression
HAM-D17 score ≥ 17
Good general medical health; no active significant uncontrolled medical illness
Free of antidepressant medication for a minimum of 6 weeks before study entry
Not "needle phobic" by self report
You may not be if
Axis I and II disorders including: Bipolar, Obsessive Compulsive Disorder, Psychosis, or Antisocial or Borderline Personality Disorder with suicidal risk
Major Depression with Psychotic Features
Actively suicidal
Recent (6 month) history of substance or alcohol dependence (DSM-IV criteria)
Meditation practice once or more per week
Yoga practice more than twice per week at study entry
Mini Mental Status Exam score \< 25or history of neurologic illness
Clareo Health | Mindfulness-Based Cognitive Therapy Effect on Depression and C-Reactive Protein Levels After 8 Weeks of Treatment
